Wockhardt liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

7.16×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.61×	1.61×	1.21×	0.74×	0.56×
1.06×	1.06×	0.85×	0.51×	0.37×
629	629	534	505	90.0
984	984	423	−718	−1,521

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health

₹ CrorePeersBIOCON SYNGENE ASTERDM GLAND PPLPHARMA COHANCE LALPATHLAB NATCOPHARMMcap ₹31,151 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	7.16
Current Ratio	0.56	0.74	1.21	1.61	1.61
Quick Ratio	0.37	0.51	0.85	1.06	1.06
Cash, Equiv & ST Investments	90.0	505.0	534.0	629.0	629.0
Working Capital	-1,521.0	-718.0	423.0	984.0	984.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.